Physician
Ikids Pediatric Care PLLC
Ikids Pediatric Care PLLC was paid $2.93M by Medicaid between Aug 2021 and Dec 2024, across 85 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 31% of everything it billed.
33Billing provider infoIKIDS PEDIATRIC CARE PLLC
FORT WORTH, TX 76134
FORT WORTH, TX 76134
33aNPI1033783451assigned 05/19/2021
33bProvider typePediatrics Physician
28Total paid$2.93M
24GClaims125,676
24DCodes billed85
24AFirst – last monthAug 2021 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#159 of 1,136
Median peer was paid$329K
This provider vs. median8.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 10,008 | $209K | |
| 2022 | 35,881 | $815K | |
| 2023 | 38,003 | $910K | |
| 2024incomplete | 41,784 | $996K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 31% | 17,530 | 15,543 | $900K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 9.0% | 6,518 | 6,002 | $263K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 7.0% | 10,983 | 8,286 | $204K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.6% | 5,377 | 4,827 | $193K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.5% | 2,640 | 2,598 | $190K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.9% | 2,609 | 2,430 | $173K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.7% | 2,110 | 2,073 | $167K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4.6% | 10,541 | 9,709 | $134K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.9% | 1,326 | 1,307 | $114K |
| 99383 | 2.4% | 994 | 949 | $71K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.4% | 11,826 | 6,375 | $70K |
| 99429 | 2.2% | 2,135 | 2,073 | $64K |
73 more codes
| 87428 | 2.0% | 900 | $59K | |
| 99203 | Doctor's office visit, new patient (routine) | 1.6% | 1,014 | $46K |
| 99384 | 1.4% | 547 | $41K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 2,636 | $33K |
| 99381 | 1.1% | 528 | $31K | |
| 99382 | 1.0% | 478 | $30K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,109 | $22K |
| 94375 | <1% | 674 | $20K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 259 | $18K |
| 87807 | <1% | 1,695 | $17K | |
| 94010 | <1% | 640 | $14K | |
| 83655 | <1% | 829 | $8K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 578 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 887 | $7K |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 2,578 | $6K |
| 99461 | <1% | 111 | $5K | |
| 96160 | <1% | 2,622 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 160 | $3K |
| 92567 | <1% | 224 | $3K | |
| 94060 | <1% | 78 | $3K | |
| 81002 | <1% | 961 | $2K | |
| 90461 | <1% | 1,436 | $2K | |
| 0071A | <1% | 84 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 526 | $1K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 163 | $713.83 |
| 90480 | <1% | 26 | $630.02 | |
| 83013 | <1% | 12 | $622.38 | |
| 94761 | <1% | 199 | $383.17 | |
| 90473 | <1% | 637 | $353.28 | |
| 85018 | <1% | 146 | $218.90 | |
| 94760 | <1% | 170 | $215.60 | |
| 90619 | <1% | 508 | $96.46 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 74 | $89.76 |
| 83014 | <1% | 12 | $72.60 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 125 | $50.59 |
| 81003 | <1% | 29 | $41.19 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 4,620 | $15.53 |
| 91307 | <1% | 233 | $2.16 | |
| 90677 | <1% | 802 | $1.95 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 116 | $1.12 |
| 97802 | <1% | 2,142 | $0.96 | |
| 90697 | <1% | 411 | $0.96 | |
| 90686 | <1% | 1,831 | $0.06 | |
| 90670 | <1% | 1,222 | $0.05 | |
| 90723 | <1% | 1,057 | $0.05 | |
| 90648 | <1% | 1,544 | $0.04 | |
| 90681 | <1% | 921 | $0.03 | |
| 90651 | <1% | 1,028 | $0.02 | |
| 90381 | <1% | 26 | $0.02 | |
| 91321 | <1% | 27 | $0.01 | |
| 90700 | 0% | 494 | $0.00 | |
| 90633 | 0% | 1,112 | $0.00 | |
| 90707 | 0% | 390 | $0.00 | |
| 90710 | 0% | 360 | $0.00 | |
| 90715 | 0% | 204 | $0.00 | |
| 90734 | 0% | 136 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 37 | $0.00 |
| 99173 | 0% | 33 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 1,513 | $0.00 |
| 96161 | 0% | 1,200 | $0.00 | |
| M0249 | Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose | 0% | 13 | $0.00 |
| 96127 | 0% | 1,123 | $0.00 | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | 0% | 63 | $0.00 |
| 90716 | 0% | 407 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 447 | $0.00 |
| 90696 | 0% | 306 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 52 | $0.00 |
| 90694 | 0% | 148 | $0.00 | |
| 90656 | 0% | 371 | $0.00 | |
| 36416 | 0% | 580 | $0.00 | |
| 90620 | 0% | 356 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 55 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 52 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGUTIERREZ, YESENIA (DO (OWNER))